Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Ohno Y, Masamoto T, Sakamoto H, Kato A, Washio Y, Hayashi M
Department of Otolaryngology, Osaka City University Medical School, Abeno, Osaka, Japan.
Laryngoscope. 1997 Jul;107(7):932-5. doi: 10.1097/00005537-199707000-00019.
Soluble intercellular adhesion molecule-1 (sICAM-1) in sera was measured in some allergic disorders, but serum sICAM-1 levels in perennial allergic rhinitis remain to be determined. Our study was aimed at elucidating whether the serum sICAM-1 levels in patients with perennial allergic rhinitis are different from those in nonatopic healthy volunteers and whether immunotherapy can modulate sICAM-1 levels. Serum sICAM-1 was determined in 20 nonallergic volunteers and 137 patients with perennial allergic rhinitis by a sandwich enzyme-linked immunosorbent assay. Our study demonstrated that the level of sICAM-1 in untreated patients is significantly elevated, as compared with nonatopic subjects. Immunotherapy could decrease sICAM-1 in perennial allergic rhinitis, but this suppressive effect became apparent only after many years of immunotherapy. In patients on immunotherapy, a close correlation was observed between sICAM-1 and nasal symptom scores. To take these lines of evidence together, a decrease in sICAM-1 might be related to the working mechanism of immunotherapy, and serum sICAM-1 could be used to monitor the effect of immunotherapy.
我们检测了一些过敏性疾病患者血清中的可溶性细胞间黏附分子-1（sICAM-1），但常年性变应性鼻炎患者的血清sICAM-1水平仍有待确定。我们的研究旨在阐明常年性变应性鼻炎患者的血清sICAM-1水平是否与非特应性健康志愿者不同，以及免疫疗法是否能调节sICAM-1水平。采用夹心酶联免疫吸附试验测定了20名非过敏性志愿者和137例常年性变应性鼻炎患者的血清sICAM-1。我们的研究表明，与非特应性受试者相比，未经治疗的患者sICAM-1水平显著升高。免疫疗法可降低常年性变应性鼻炎患者的sICAM-1水平，但这种抑制作用只有在多年免疫治疗后才会明显显现。在接受免疫治疗的患者中，观察到sICAM-1与鼻部症状评分之间存在密切相关性。综合这些证据，sICAM-1的降低可能与免疫疗法的作用机制有关，血清sICAM-1可用于监测免疫疗法的效果。
